AMSBIO announce the availability of recombinant proteins and antibodies for detection of Coronavirus (COVID-19) and related RNA viruses.

Historically strains of Coronavirus able to infect humans (HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoVHKU1) were not highly pathogenic and only caused mild respiratory illness. By comparison more recent strains - SARS-CoV, MERS-CoV and COVID-19 that emerged in Wuhan, China at the end of 2019 are highly pathogenic resulting in large scale pandemics.

AMSBIO offers a Skeletal Muscle Differentiation kit that enables you to differentiate human pluripotent stem cells to skeletal muscle myotubes with high yields, without cell sorting or genetic manipulation. Myotubes are contractile, express typical muscle markers that show striated sarcomeres.

If you work in the biotech, pharma, medical or related scientific area, and have marketing goals for 2020 - we would be grateful if you could fill out our 1 min marketing survey.

Onyva The Agency is looking for your expert input on its (very) short survey, to help serve the sector better. The poll includes entry into an optional prize draw of £100 worth of office treats. Anonymized results will be sent to participants.

Cambridge 05 March 2020: Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures within the active Babraham Research Campus community. As part of this initiative StartUP@Babraham is a competition specifically to support ideas and/or companies that are pre-seed to seed stage (below £500k investment).

A Newcastle medtech company has secured nearly £250,000 in funding from Innovate UK to further its research into the impact of genetics on implants.

Based in The Biosphere on Newcastle Helix, ExplantLab combines extensive medical, bioengineering and surgical knowledge to further understand explants (implants that have been removed from the body). Having opened last year with both chemistry and biology laboratories, The Biosphere is already close to 50 per cent full and is home to a host of innovative life sciences companies.

Westbury, NY – Mar. 3, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, announced that it is now providing same-day delivery of fresh blood, LEUKOMAX® leukopaks and buffy coats from normal and disease-state donors to cell and gene therapy researchers in the UK. BioIVT is also shipping these products overnight to certain EU locations.

Cambridge, UK, 2nd March 2020: CN Bio Innovations (“CN Bio”), a leading cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, today announced it has raised $9 million USD (circa £6.9 million GBP) investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations Holdings Ltd.

Cambridge, UK, and Saluggia, Italy, 02 March 2020: TTP plc (TTP), a leading independent technology and product development company, and DiaSorin, a global leader in the in vitro diagnostic (IVD) field, have signed an exclusive licence and technology transfer agreement. DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx™ platform to develop a single-use, sample-to-answer, molecular diagnostics point-of-care platform for human IVD applications.

Cambridge, UK, 02 March 2020: PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.